Daniel Flaherty, MD
Obstetrics & Gynecology · Georgetown, SCNPI 1386602449
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.2% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 23.1% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for obstetrics & gynecology clinicians in SC, where the typical reported total is $718.
Across 44 payments — averaging $14.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$151
- AbbVie$112
- Grifols USA, LLC$106
- Daiichi Sankyo Inc.$36
- Astellas Pharma US Inc$34
- Amgen$28
- plus $186 from 11 others
Across 53 payments — averaging $971.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$52K
What the payments were for
- Food & beverage$62195%
- Education$315%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 10 | $151 |
| AbbVie(2 entities) | 7 | $112 |
| Grifols USA, LLC | 7 | $106 |
| Daiichi Sankyo Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $34 |
| Amgen | 2 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $26 |
| AstraZeneca | 2 | $23 |
| Amarin Pharma, Inc. | 2 | $23 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Myovant Sciences Inc. | 1 | $16 |
| Exact Sciences | 1 | $16 |
| Novo Nordisk | 1 | $13 |
| Medtronic | 1 | $13 |
| Abbott | 1 | $12 |
| Eisai Inc. | 1 | $12 |
| Merck | 1 | $12 |
How this compares
$652 in reported general payments places this provider in the 45th percentile of 673 obstetrics & gynecology providers in South Carolina.
See all obstetrics & gynecology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 11 | $5,127 |
| Estradiol | 14 | $1,447 |
| Oxybutynin Chloride ErOxybutynin Chloride | 15 | $390 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Georgetown
- Andrea Richmond-MartGeorgetown$12K
- Monica Selander-HanGeorgetown$10K
- Christopher JenningsAnderson$1.3M
- William ColemanGreenville$242K
- Melvin SeidMauldin$235K
- Brooke NaffzigerWest Columbia$70K
- Judith BurgisColumbia$59K
- Charis ChambersGreenville$46K
- Angela ChoiCharleston$43K
- Andrew FuttermanCharleston$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.